The United States Food and Drug Administration's Platform Technology Designation to Expedite the Development of Drugs
Drug development costs can be significantly reduced if proven "platform" technologies are allowed to be used without having to validate their use. The most recent US Food and Drug Administration (FDA) guideline brings more clarity, as well as a greater focus on the most complex technologie...
Saved in:
Main Author: | Sarfaraz K. Niazi (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2024-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The FDA's New Guideline "Generally Accepted Scientific Knowledge" (GASK): An Opportunity to Expedite the Approval of Biosimilars
by: Sarfaraz K. Niazi
Published: (2023) -
Computer-Aided Drug Design and Drug Discovery: A Prospective Analysis
by: Sarfaraz K. Niazi, et al.
Published: (2023) -
Non-Invasive Drug Delivery across the Blood-Brain Barrier: A Prospective Analysis
by: Sarfaraz K. Niazi
Published: (2023) -
Retrospective analysis of adverse events with spironolactone in females reported to the United States Food and Drug Administration
by: Yu Wang, BA, et al.
Published: (2020) -
Cryptosporidiosis should be designated as a tropical disease by the US Food and Drug Administration.
by: Robert K M Choy, et al.
Published: (2020)